Detalhe da pesquisa
1.
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
Clin Infect Dis
; 77(8): 1102-1110, 2023 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338158
2.
Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine.
J Infect Dis
; 223(11): 2001-2012, 2021 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33031517
3.
A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
J Virol
; 93(23)2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511385
4.
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
J Infect Dis
; 220(3): 411-419, 2019 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31535143
5.
The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C.
Hum Vaccin Immunother
; 19(2): 2235238, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37529944
6.
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Vaccine
; 41(5): 1142-1152, 2023 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621410
7.
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
Vaccine
; 41(3): 657-665, 2023 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36522265
8.
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Blood Adv
; 7(3): 414-421, 2023 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36383730
9.
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
AIDS
; 37(8): 1227-1237, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939067
10.
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
Vaccine
; 41(15): 2456-2465, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36841723
11.
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies.
Pediatr Infect Dis J
; 42(11): 1021-1028, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566897
12.
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Hum Vaccin Immunother
; 19(1): 2177066, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36864601
13.
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Vaccine
; 41(21): 3387-3398, 2023 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37105892
14.
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study.
Pediatrics
; 152(1)2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37309607
15.
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Lancet Infect Dis
; 23(2): 233-246, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36116461
16.
Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20.
Expert Rev Vaccines
; 21(1): 115-123, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672224
17.
Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).
Jpn J Infect Dis
; 75(6): 575-582, 2022 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35908869
18.
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
Vaccine
; 40(44): 6315-6325, 2022 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150974
19.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Hum Vaccin Immunother
; 18(1): 1-14, 2022 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34726574
20.
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
Vaccine
; 40(9): 1342-1351, 2022 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35039194